Trial Profile
Efficacy of vedolizumab in adult patients with of Crohn's disease and ulcerative colitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Feb 2022
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Therapeutic Use
- 14 Apr 2020 Results published in the Journal of Gastroenterology and Hepatology
- 23 May 2017 New trial record
- 09 May 2017 Results presented at the Digestive Disease Week 2017